The Medical Letter on Drugs and Therapeutics
Peginterferon Beta-1a (Plegridy) for Multiple Sclerosis
May 11, 2015 (Issue: 1468)The FDA has approved a pegylated form of interferon beta-1a (Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).
- Canadian Agency for Drugs and Technologies in Health. CADTH therapeutic review. Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis [Internet]. Ottawa: The Agency; 2013 Oct. (CADTH Therapeutic Review vol. 1, no. 26). [cited 2015 April 30]. Available at: https://www.cadth.ca.
- New drugs for multiple sclerosis. Med Lett Drugs Ther 2012; 54:89.
- Dimethyl fumarate (Tecfidera) for multiple sclerosis. Med Lett Drugs Ther 2013; 55:45.
- V Annibali et al. IFN-β and multiple sclerosis: from etiology to therapy and back. Cytokine Growth Factor Rev 2015; 26:221.
- PA Calabresi et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014; 13:657.
- BC Kieseier et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 2014 November 28 (epub).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.